Steven H. Collis Sells 10,754 Shares of Cencora, Inc. (NYSE:COR) Stock

Cencora, Inc. (NYSE:COR) CEO Steven H. Collis sold 10,754 shares of Cencora stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $237.48, for a total value of $2,553,859.92. Following the completion of the sale, the chief executive officer now owns 285,088 shares in the company, valued at $67,702,698.24. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Cencora Stock Down 0.6 %

Shares of NYSE:COR opened at $237.30 on Friday. The stock has a fifty day simple moving average of $237.53 and a two-hundred day simple moving average of $214.64. The stock has a market capitalization of $47.34 billion, a price-to-earnings ratio of 25.85, a PEG ratio of 1.82 and a beta of 0.45. Cencora, Inc. has a 12-month low of $163.37 and a 12-month high of $246.75. The company has a current ratio of 0.88, a quick ratio of 0.52 and a debt-to-equity ratio of 3.94.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $3.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.86 by $0.42. The business had revenue of $72.25 billion during the quarter, compared to analysts’ expectations of $68.81 billion. Cencora had a return on equity of 323.23% and a net margin of 0.69%. During the same quarter in the previous year, the business earned $2.71 earnings per share. On average, research analysts anticipate that Cencora, Inc. will post 13.43 earnings per share for the current fiscal year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 26th. Shareholders of record on Friday, February 9th were paid a dividend of $0.51 per share. This is a boost from Cencora’s previous quarterly dividend of $0.24. The ex-dividend date was Thursday, February 8th. This represents a $2.04 dividend on an annualized basis and a yield of 0.86%. Cencora’s payout ratio is presently 22.22%.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in COR. Measured Wealth Private Client Group LLC purchased a new position in shares of Cencora in the first quarter worth $574,000. MV Capital Management Inc. purchased a new position in shares of Cencora in the first quarter worth $82,000. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH purchased a new position in shares of Cencora in the first quarter worth $13,090,000. Dash Acquisitions Inc. purchased a new position in shares of Cencora in the first quarter worth $201,000. Finally, Allspring Global Investments Holdings LLC purchased a new position in shares of Cencora in the first quarter worth $50,337,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Mizuho lifted their price objective on Cencora from $192.00 to $224.00 and gave the stock a “neutral” rating in a research report on Monday, February 5th. SVB Leerink began coverage on Cencora in a research note on Monday, February 26th. They issued an “outperform” rating and a $261.00 target price for the company. Leerink Partnrs restated an “outperform” rating on shares of Cencora in a research note on Monday, February 26th. StockNews.com upgraded Cencora from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 1st. Finally, Barclays began coverage on Cencora in a research note on Wednesday, January 3rd. They issued an “overweight” rating and a $242.00 target price for the company. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $218.22.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.